查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1984875

全球外泌体疗法市场：依外泌体来源、治疗方法、治疗环境、治疗应用案例、给药方法、监管分类和地区划分－市场规模、产业动态、机会分析和预测（2026-2035 年）

Global Exosome Therapy Market: By Exosome Source Type, Treatment Setting, Therapeutic Use Case, Administration Approach, Regulatory Classification, Region - Market Size, Industry Dynamics, Opportunity Analysis and Forecast for 2026-2035
出版日期: | 出版商: Astute Analytica | 英文 320 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

外泌体疗法市场正在经历重大转型，从一个投机性的小众领域发展成为一个快速成长且具有显着经济价值的产业。目前，该市场价值 581 亿美元，预计未来几年将实现显着成长，到 2035 年将超过 3,096 亿美元。这一显着扩张意味着 2026 年至 2035 年期间的复合年增长率 (CAGR) 将达到 18.20%，凸显了投资者信心的增强以及基于外泌体的疗法日益普及。

推动该市场发展的关键因素之一是从传统的基于活干细胞的疗法转向 "无细胞" 外泌体产品。 这种转变源自于人们希望解决干细胞疗法面临的挑战，特别是安全性和可扩展性方面的担忧。外泌体是由细胞分泌的微小细胞外囊泡，是一种很有前景的替代方案，因为它们保留了干细胞的许多治疗效果，而没有细胞本身固有的风险。

主要市场趋势

该行业的特点是竞争激烈，公司类型多样，包括成熟的生物製药公司、专业的生物技术公司和研究工具供应商。这种组合造就了一个充满活力的环境，创新和策略举措对于成功至关重要。每种类型的公司都为市场带来独特的优势，从先进的研究能力到专业的技术平台，共同构成了一个丰富多元的竞争格局。

推动该领域发展的关键公司包括 Coya Therapeutics、Evox Therapeutics、Curexsys、EV Therapeutics、SHIFTBIO、Capriccio Therapeutics 和 Aethlon Medical。 这些公司不仅在推动自身技术发展，也积极透过各种策略措施来巩固其市场地位。

除了建立合作关係外，这些公司还在大力投资开发符合良好生产规范 (GMP) 标准的可扩展生产技术。 这项措施确保生产流程符合严格的监管要求，这是生物製药安全稳定生产的关键要素。

主要成长驱动因素

全球癌症发生率的上升是推动基于外泌体的免疫疗法和标靶药物递送系统需求的关键因素。随着全球癌症发生率的持续上升，迫切需要开发更有效、更精准的疗法，以改善患者预后并最大限度地减少副作用。基于外泌体的疗法因其能够调节免疫系统并将治疗药物高特异性地直接递送至肿瘤细胞，而备受关注。

新兴机会

外泌体疗法市场最具获利潜力的机会不仅存在于再生医学领域，也存在于药物递送领域。再生医学因其修復和癒合受损组织的能力而备受关注，而外泌体作为一种高效的药物递送载体，其潜力正在成为一个具有更大商业前景的创新领域。 全球生物製药市场现有药物递送系统的局限性，主要依赖脂质奈米颗粒（LNP）和病毒载体，这为外泌体疗法市场的发展提供了机会。儘管这些技术已取得显着成功，但它们往往存在一些重大缺陷，例如毒性或诱发免疫反应。

优化障碍

由于产业缺乏标准化和品质控制，外泌体疗法市场的成长面临严峻挑战。目前，外泌体的分离、表征和生产尚无普遍接受的方案，促使这些疗法的生产方法有显着差异。缺乏标准化流程导致批次间差异显着，通常超过20%，这意味着外泌体产品的组成和品质可能因批次而异。这种异质性会削弱治疗效果的可靠性和可预测性，而这些对于赢得临床医生、患者和监管机构的信任至关重要。

目录

第一章 摘要整理：全球外泌体疗法市场

第二章 研究方法与架构

  • 研究目标
  • 产品概述
  • 市场区隔
  • 质性研究
    • 一手和二手资料
  • 量化研究
    • 一手和二手资料
  • 主要调查受访者分布：依地区划分
  • 本研究的假设
  • 市场规模估算
  • 数据三角测量

第三章 全球外泌体疗法市场概论

  • 产业价值链分析
    • 原料和生物材料供应商
    • 外泌体分离与生产技术供应商
    • 合约开发与生产组织 (CDMO)
    • 治疗开发公司和生技公司
    • 医疗保健提供者和临床机构
  • 行业展望
    • 临床开发趋势
    • 监理环境
    • 疾病负担与治疗潜力
  • PESTLE 分析
  • 波特五力分析
    • 供应商议价能力
    • 买方议价能力
    • 替代品威胁
    • 新进入者威胁
    • 竞争强度
  • 市场成长与展望
    • 市场收入估算与预测（2020-2035 年）
    • 价格趋势分析

第四章 全球外泌体疗法市场分析

  • 竞争格局概览
    • 市场集中度
    • 公司占有率分析（价值，%），2025 年
    • 竞争对手分析与基准分析

第五章 全球外泌体疗法市场分析

  • 市场动态与趋势
    • 成长驱动因素
    • 限制因素
    • 机遇
    • 主要趋势
  • 市场规模及预测（2020-2035 年）
    • 依治疗方法
    • 依治疗环境
    • 依给药方法
    • 依外泌体类型来源
    • 依监理分类
    • 治疗用途
    • 依地区

第六章：北美市场分析

第七章：欧洲市场分析

第八章：亚太市场分析

第九章：中东和非洲市场分析

第十章：南美市场分析

第11章 企业简介

  • Aethlon Medical Inc.
  • Capricor Therapeutics Inc.
  • Codiak BioSciences
  • EV Therapeutics
  • Evox Therapeutics Ltd.
  • Exosome Sciences Inc.
  • ReNeuron Group plc
  • System Biosciences LLC
  • Aruna Bio, Inc.
  • NurExone Biologic
  • Aegle Therapeutics
  • Other Prominent Players

第12章 附录

简介目录
Product Code: AA01261686

The exosome therapy market is undergoing a significant transformation, evolving from a speculative and niche segment into a rapidly expanding industry with substantial economic value. Currently valued at USD 58.1 billion, the market is projected to experience impressive growth over the coming years, with forecasts estimating it will exceed USD 309.6 billion by 2035. This remarkable expansion reflects a compound annual growth rate (CAGR) of 18.20% during the period from 2026 to 2035, highlighting both increasing investor confidence and growing adoption of exosome-based therapies.

One of the key factors driving this market evolution is the shift from traditional live stem cell therapies toward "cell-free" exosome products. This transition is motivated by the desire to address some of the challenges associated with stem cell treatments, particularly concerns related to safety and scalability. Exosomes, which are small extracellular vesicles secreted by cells, offer a promising alternative because they carry many of the therapeutic benefits of stem cells without the risks linked to the cells themselves.

Noteworthy Market Developments

The industry is characterized by intense competition and a diverse array of players, including well-established biopharmaceutical companies, specialized biotechnology firms, and providers of research tools. This blend creates a dynamic landscape where innovation and strategic maneuvering are essential for success. Each type of company brings unique strengths to the market, from advanced research capabilities to specialized technology platforms, contributing to a rich and multifaceted competitive environment.

Among the key participants driving progress in this sector are companies such as Coya Therapeutics, Evox Therapeutics, Curexsys, EV Therapeutics, SHIFTBIO, Capricor Therapeutics, and Aethlon Medical. These organizations are not only advancing their proprietary technologies but also actively seeking to strengthen their market positions through various strategic initiatives.

In addition to forging alliances, these companies are heavily investing in the development of scalable production technologies that comply with Good Manufacturing Practice (GMP) standards. This focus ensures that their manufacturing processes meet stringent regulatory requirements, which is crucial for the safe and consistent production of biopharmaceutical products.

Core Growth Drivers

The increasing global incidence of cancer is a significant factor driving the demand for exosome-based immunotherapy and targeted drug delivery systems. As cancer rates continue to rise worldwide, there is an urgent need for more effective and precise treatment options that can improve patient outcomes while minimizing side effects. Exosome-based therapies have garnered considerable attention in this context because of their ability to modulate the immune system and deliver therapeutic agents directly to tumor cells with high specificity.

Emerging Opportunity Trends

The most lucrative opportunity within the exosome therapy market extends beyond regenerative treatments and lies in the domain of drug delivery. While regenerative therapies have garnered significant attention for their ability to repair and heal damaged tissues, the potential of exosomes as highly efficient drug delivery vehicles is emerging as a transformative frontier with even greater commercial promise. This opportunity is driven by the limitations of current drug delivery systems in the global biologics market, which predominantly depend on Lipid Nanoparticles (LNPs) and viral vectors. Although these technologies have achieved considerable success, they are often accompanied by significant drawbacks, such as triggering toxicity or provoking immune responses.

Barriers to Optimization

The growth of the exosome therapy market faces significant challenges due to the lack of standardization and quality control across the industry. Currently, there are no universally accepted protocols for the isolation, characterization, and manufacturing of exosomes, which creates considerable variability in how these therapies are produced. This absence of standardized procedures results in high batch-to-batch variability, often exceeding 20%, meaning that the composition and quality of exosome products can differ substantially from one production run to another. Such inconsistencies undermine the reliability and predictability of therapeutic outcomes, which are critical factors for gaining the trust of clinicians, patients, and regulators alike.

Detailed Market Segmentation

By treatment setting, the hospital-based therapies segment emerged as the largest treatment setting within the exosome therapy market, capturing a significant market share of 39%. This leadership position is largely attributed to the nature of the conditions treated and the complexity involved in administering certain exosome therapies. Many of these therapies, particularly those designed for acute and severe conditions such as Acute Respiratory Distress Syndrome (ARDS), require careful and continuous inpatient monitoring to ensure patient safety and optimal therapeutic outcomes.

By therapeutic use case, the regenerative therapies segment holds a commanding position within the exosome therapy market, securing a leading market share of 52% in 2025. This dominance is largely driven by the clinical validation of exosomes' remarkable ability to accelerate tissue repair, especially in the treatment of chronic wounds. Unlike traditional cell-based grafts, which often involve complex procedures and carry risks such as immune rejection or limited integration, exosome therapies offer a more efficient and less invasive alternative.

By exosome source type, the stem cell-derived exosomes segment stood out by securing the largest market share, commanding an impressive 62% in 2025. This dominant position reflects the unique biological advantages that stem cell-derived exosomes offer compared to other sources. Among stem cells, Mesenchymal Stem Cells (MSCs) have emerged as the preferred "bio-factories" within the industry. MSCs are especially valued because their exosomes are naturally enriched with a diverse array of bioactive lipids and proteins that play critical roles in tissue repair and regeneration.

By therapy modality, the autologous exosome therapy category emerged as the clear leader, capturing the largest market share of 57% in 2025. This dominance is firmly grounded in scientific rationale, as autologous therapies utilize exosomes derived directly from the patient's own cells. This approach offers superior biocompatibility, significantly minimizing the risk of immune rejection that can occur with allogeneic therapies, which use exosomes sourced from donors. Because the exosomes are patient-specific, they are more readily accepted by the body's immune system, enhancing both safety and therapeutic efficacy.

Segment Breakdown

By Therapy Modality

  • Autologous Exosome Therapy
  • Patient-derived cell exosomes
  • Point-of-care or near-patient processing
  • Allogeneic Exosome Therapy
  • Donor-derived standardized exosomes
  • Off-the-shelf exosome preparations

By Treatment Setting

  • Hospital-based therapies
  • Specialty clinics
  • Orthopedic clinics
  • Neurology clinics
  • Oncology clinics
  • Ambulatory surgical centers
  • Wellness/aesthetic centers

By Therapeutic Use Case

  • Regenerative therapies
  • Musculoskeletal repair
  • Wound healing
  • Anti-inflammatory therapies
  • Neurorestorative therapies
  • Cardiometabolic therapies
  • Aesthetic & cosmetic therapies
  • Skin rejuvenation
  • Hair restoration
  • Supportive/adjunctive therapies

By Administration Approach

  • Systemic therapy
  • IV-based exosome therapy
  • Local therapy
  • Intra-articular
  • Intradermal
  • Intrathecal
  • Topical application

By Exosome Source Type

  • Stem cell-derived exosomes
  • Immune cell-derived exosomes
  • Tissue-derived exosomes
  • Plant-derived exosomes

By Regulatory Classification

  • Regulated therapeutic procedures
  • Compassionate-use / experimental therapies
  • Non-regulated / wellness-based therapies

By Region

  • North America
  • Europe
  • Asia Pacific
  • Middle East and Africa
  • South America

Geography Breakdown

  • North America is not only leading the global exosome therapy market but is also setting the standards that other regions are beginning to follow. In 2025, the region commands a substantial 46.80% share of the market, highlighting its pivotal role in shaping the future of exosome therapies worldwide. This dominance is largely attributed to the region's regulatory environment, which embraces a "high-risk, high-reward" approach. This framework encourages innovation by allowing promising therapies to advance rapidly through clinical development while providing clear pathways for regulatory approval.
  • A major milestone that catalyzed North America's leadership was the historic filing on January 2, 2025, of the first Biologics License Application (BLA) by Capricor Therapeutics. This event was a watershed moment because it effectively positioned the U.S. Food and Drug Administration (FDA) as the global gatekeeper for exosome therapy approvals. The FDA's clear regulatory stance provided much-needed clarity and legitimacy to the field, alleviating uncertainties that had previously slowed investment and development. As a result, venture capitalists gained increased confidence in the market's potential, leading to a surge in funding.

Leading Market Participants

  • Aethlon Medical Inc.
  • Bluebird Bio Inc.
  • Capricor Therapeutics Inc.
  • Codiak BioSciences Inc.
  • EV Therapeutics
  • Evox Therapeutics Ltd.
  • Exosome Sciences Inc.
  • Invivo Therapeutics Holdings Corp.
  • Kintor Pharmaceutical Limited
  • MBR Therapeutics
  • Medivir AB
  • NanoString Technologies Inc.
  • ReNeuron Group plc
  • Sorrento Therapeutics Inc.
  • System Biosciences LLC
  • Other Prominent Players

Table of Content

Chapter 1. Executive Summary: Global Exosome Therapy Market

Chapter 2. Research Methodology & Research Framework

  • 2.1. Research Objective
  • 2.2. Product Overview
  • 2.3. Market Segmentation
  • 2.4. Qualitative Research
    • 2.4.1. Primary & Secondary Sources
  • 2.5. Quantitative Research
    • 2.5.1. Primary & Secondary Sources
  • 2.6. Breakdown of Primary Research Respondents, By Region
  • 2.7. Assumption for Study
  • 2.8. Market Size Estimation
  • 2.9. Data Triangulation

Chapter 3. Global Exosome Therapy Market Overview

  • 3.1. Industry Value Chain Analysis
    • 3.1.1. Raw Material & Biological Source Providers
    • 3.1.2. Exosome Isolation & Manufacturing Technology Providers
    • 3.1.3. Contract Development & Manufacturing Organizations (CDMOs)
    • 3.1.4. Therapy Developers & Biotechnology Companies
    • 3.1.5. Healthcare Providers & Clinical Institutions
  • 3.2. Industry Outlook
    • 3.2.1. Clinical Development Landscape
    • 3.2.2. Regulatory Landscape
    • 3.2.3. Disease Burden & Therapeutic Potential
  • 3.3. PESTLE Analysis
  • 3.4. Porter's Five Forces Analysis
    • 3.4.1. Bargaining Power of Suppliers
    • 3.4.2. Bargaining Power of Buyers
    • 3.4.3. Threat of Substitutes
    • 3.4.4. Threat of New Entrants
    • 3.4.5. Degree of Competition
  • 3.5. Market Growth and Outlook
    • 3.5.1. Market Revenue Estimates and Forecast (US$ Mn), 2020-2035
    • 3.5.2. Price Trend Analysis

Chapter 4. Global Exosome Therapy Market Analysis

  • 4.1. Competition Dashboard
    • 4.1.1. Market Concentration Rate
    • 4.1.2. Company Market Share Analysis (Value %), 2025
    • 4.1.3. Competitor Mapping & Benchmarking

Chapter 5. Global Exosome Therapy Market Analysis

  • 5.1. Market Dynamics and Trends
    • 5.1.1. Growth Drivers
    • 5.1.2. Restraints
    • 5.1.3. Opportunity
    • 5.1.4. Key Trends
  • 5.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 5.2.1. By Therapy Modality
      • 5.2.1.1. Key Insights
        • 5.2.1.1.1. Autologous Exosome Therapy
          • 5.2.1.1.1.1. Patient-derived cell exosomes
          • 5.2.1.1.1.2. Point-of-care or near-patient processing
        • 5.2.1.1.2. Allogeneic Exosome Therapy
          • 5.2.1.1.2.1. Donor-derived standardized exosomes
          • 5.2.1.1.2.2. Off-the-shelf exosome preparations
    • 5.2.2. By Treatment Setting
      • 5.2.2.1. Key Insights
        • 5.2.2.1.1. Hospital-based therapies
        • 5.2.2.1.2. Specialty clinics
          • 5.2.2.1.2.1. Orthopedic clinics
          • 5.2.2.1.2.2. Neurology clinics
          • 5.2.2.1.2.3. Oncology clinics
        • 5.2.2.1.3. Ambulatory surgical centers
        • 5.2.2.1.4. Wellness/aesthetic centers
    • 5.2.3. By Administration Approach
      • 5.2.3.1. Key Insights
        • 5.2.3.1.1. Systemic Administration
          • 5.2.3.1.1.1. Intravenous (IV)
        • 5.2.3.1.2. Localized Administration
          • 5.2.3.1.2.1. Intra-articular
          • 5.2.3.1.2.2. Intradermal
          • 5.2.3.1.2.3. Intrathecal
          • 5.2.3.1.2.4. Topical application
    • 5.2.4. By Exosome Source Type
      • 5.2.4.1. Key Insights
        • 5.2.4.1.1. Stem cell-derived exosomes
        • 5.2.4.1.2. Immune cell-derived exosomes
        • 5.2.4.1.3. Tissue-derived exosomes
        • 5.2.4.1.4. Plant-derived exosomes
    • 5.2.5. By Regulatory Classification
      • 5.2.5.1. Key Insights
        • 5.2.5.1.1. Regulated therapeutic procedures
        • 5.2.5.1.2. Compassionate-use / experimental therapies
        • 5.2.5.1.3. Non-regulated / wellness-based therapies
    • 5.2.6. By Therapeutic Use Case
      • 5.2.6.1. Key Insights
        • 5.2.6.1.1. Regenerative therapies
          • 5.2.6.1.1.1. Musculoskeletal repair
          • 5.2.6.1.1.2. Wound healing
        • 5.2.6.1.2. Anti-inflammatory therapies
        • 5.2.6.1.3. Neurorestorative therapies
        • 5.2.6.1.4. Cardiometabolic therapies
        • 5.2.6.1.5. Aesthetic & cosmetic therapies
          • 5.2.6.1.5.1. Skin rejuvenation
          • 5.2.6.1.5.2. Hair restoration
        • 5.2.6.1.6. Supportive/adjunctive therapies
    • 5.2.7. By Region
      • 5.2.7.1. Key Insights
        • 5.2.7.1.1. North America
          • 5.2.7.1.1.1. The U.S.
          • 5.2.7.1.1.2. Canada
          • 5.2.7.1.1.3. Mexico
        • 5.2.7.1.2. Europe
          • 5.2.7.1.2.1. Western Europe
            • 5.2.7.1.2.1.1. The UK
            • 5.2.7.1.2.1.2. Germany
            • 5.2.7.1.2.1.3. France
            • 5.2.7.1.2.1.4. Italy
            • 5.2.7.1.2.1.5. Spain
            • 5.2.7.1.2.1.6. Rest of Western Europe
          • 5.2.7.1.2.2. Eastern Europe
            • 5.2.7.1.2.2.1. Poland
            • 5.2.7.1.2.2.2. Russia
            • 5.2.7.1.2.2.3. Rest of Eastern Europe
        • 5.2.7.1.3. Asia Pacific
          • 5.2.7.1.3.1. China
          • 5.2.7.1.3.2. India
          • 5.2.7.1.3.3. Japan
          • 5.2.7.1.3.4. South Korea
          • 5.2.7.1.3.5. Australia & New Zealand
          • 5.2.7.1.3.6. ASEAN
            • 5.2.7.1.3.6.1. Indonesia
            • 5.2.7.1.3.6.2. Malaysia
            • 5.2.7.1.3.6.3. Thailand
            • 5.2.7.1.3.6.4. Singapore
            • 5.2.7.1.3.6.5. Rest of ASEAN
          • 5.2.7.1.3.7. Rest of Asia Pacific
        • 5.2.7.1.4. Middle East & Africa
          • 5.2.7.1.4.1. UAE
          • 5.2.7.1.4.2. Saudi Arabia
          • 5.2.7.1.4.3. South Africa
          • 5.2.7.1.4.4. Rest of MEA
        • 5.2.7.1.5. South America
          • 5.2.7.1.5.1. Argentina
          • 5.2.7.1.5.2. Brazil
          • 5.2.7.1.5.3. Rest of South America

Chapter 6. North America Market Analysis

  • 6.1. Market Dynamics and Trends
    • 6.1.1. Growth Drivers
    • 6.1.2. Restraints
    • 6.1.3. Opportunity
    • 6.1.4. Key Trends
  • 6.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 6.2.1. Key Insights
      • 6.2.1.1. By Therapy Modality
      • 6.2.1.2. By Treatment Setting
      • 6.2.1.3. By Administration Approach
      • 6.2.1.4. By Exosome Source Type
      • 6.2.1.5. By Regulatory Classification
      • 6.2.1.6. By Therapeutic Use Case
      • 6.2.1.7. By Country

Chapter 7. Europe Market Analysis

  • 7.1. Market Dynamics and Trends
    • 7.1.1. Growth Drivers
    • 7.1.2. Restraints
    • 7.1.3. Opportunity
    • 7.1.4. Key Trends
  • 7.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 7.2.1. Key Insights
      • 7.2.1.1. By Therapy Modality
      • 7.2.1.2. By Treatment Setting
      • 7.2.1.3. By Administration Approach
      • 7.2.1.4. By Exosome Source Type
      • 7.2.1.5. By Regulatory Classification
      • 7.2.1.6. By Therapeutic Use Case
      • 7.2.1.7. By Country

Chapter 8. Asia Pacific Market Analysis

  • 8.1. Market Dynamics and Trends
    • 8.1.1. Growth Drivers
    • 8.1.2. Restraints
    • 8.1.3. Opportunity
    • 8.1.4. Key Trends
  • 8.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 8.2.1. Key Insights
      • 8.2.1.1. By Therapy Modality
      • 8.2.1.2. By Treatment Setting
      • 8.2.1.3. By Administration Approach
      • 8.2.1.4. By Exosome Source Type
      • 8.2.1.5. By Regulatory Classification
      • 8.2.1.6. By Therapeutic Use Case
      • 8.2.1.7. By Country

Chapter 9. Middle East & Africa Market Analysis

  • 9.1. Market Dynamics and Trends
    • 9.1.1. Growth Drivers
    • 9.1.2. Restraints
    • 9.1.3. Opportunity
    • 9.1.4. Key Trends
  • 9.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 9.2.1. Key Insights
      • 9.2.1.1. By Therapy Modality
      • 9.2.1.2. By Treatment Setting
      • 9.2.1.3. By Administration Approach
      • 9.2.1.4. By Exosome Source Type
      • 9.2.1.5. By Regulatory Classification
      • 9.2.1.6. By Therapeutic Use Case
      • 9.2.1.7. By Country

Chapter 10. South America Market Analysis

  • 10.1. Market Dynamics and Trends
    • 10.1.1. Growth Drivers
    • 10.1.2. Restraints
    • 10.1.3. Opportunity
    • 10.1.4. Key Trends
  • 10.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 10.2.1. Key Insights
      • 10.2.1.1. By Therapy Modality
      • 10.2.1.2. By Treatment Setting
      • 10.2.1.3. By Administration Approach
      • 10.2.1.4. By Exosome Source Type
      • 10.2.1.5. By Regulatory Classification
      • 10.2.1.6. By Therapeutic Use Case
      • 10.2.1.7. By Country

Chapter 11. Company Profile (Company Overview, Financial Matrix, Key Product landscape, Key Personnel, Key Competitors, Contact Address, and Business Strategy Outlook)

  • 11.1. Aethlon Medical Inc.
  • 11.2. Capricor Therapeutics Inc.
  • 11.3. Codiak BioSciences
  • 11.4. EV Therapeutics
  • 11.5. Evox Therapeutics Ltd.
  • 11.6. Exosome Sciences Inc.
  • 11.7. ReNeuron Group plc
  • 11.8. System Biosciences LLC
  • 11.9. Aruna Bio, Inc.
  • 11.10. NurExone Biologic
  • 11.11. Aegle Therapeutics
  • 11.12. Other Prominent Players

Chapter 12. Annexure

  • 12.1. List of Secondary Sources
  • 12.2. Key Country Markets- Macro Economic Outlook/Indicators